Skip to main content
Log in

Brimonidine: a useful new topical treatment for glaucoma and ocular hypertension

  • New Drugs and Disease Management
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Quigley HA. Open-angle glaucoma. N Engl J Med 1993 Apr; 328(15): 1097–106

    Article  PubMed  CAS  Google Scholar 

  2. Adkins JC, Balfour JA. Brimonidine: a review of its pharmacological properties and clinical potential in the management of open-angle glaucoma and ocular hypertension. Drugs Aging 1998 Mar; 12(3): 225–41

    Article  PubMed  CAS  Google Scholar 

  3. Derick RJ, Robin AL, Walters TR, et al. Brimonidine tartrate: a one-month dose response study. Ophthalmology 1997 Jan; 104: 131–6

    PubMed  CAS  Google Scholar 

  4. Serle JB. A comparison of the safety and efficacy of twice daily brimonidine 0.2% versus betaxolol 0.25% in subjects with elevated intraocular pressure. Surv Ophthalmol 1996 Nov; 41 Suppl. 1: S39–47

    Article  PubMed  Google Scholar 

  5. Schuman JS. Clinical experience with brimonidine 0.2% and timolol 0.5% in glaucoma and ocular hypertension. Surv Ophthalmol 1996 Nov; 41 Suppl. 1: 27–37

    Article  Google Scholar 

  6. Gandolfi SA. The additive effect of brimonidine 0.2% BID compared with pilocarpine 2.0% TID in patients on beta-blocker monotherapy (abstract). Joint European Research Meeting in Ophthalmology and Vision (JERMOV); 1997 Oct 15–19: Montpelier

  7. Allergan Limited. Alphagan®. ABPI Compendium of Data Sheets and Summaries of Product Characteristics 1998–99. London: Datapharm Publications Ltd: 54–5

    Google Scholar 

  8. Allergan Inc. Brimonidine tartrate. PDR Generics 1998. Montvale (NJ): Medical Economics: 375

    Google Scholar 

  9. Abel Jr RS, Abel AD. Ocular diseases. In: Speight TM, Holford NHG, editors. Avery’s drug treatment. 4th ed. Auckland: Adis International Limited, 1997: 581–605

    Google Scholar 

  10. Brooks AMV, Gillies WE. Ocular β-blockers in glaucoma management: clinical pharmacological aspects. Drugs Aging 1992 May–Jun; 2: 208–21

    Article  PubMed  CAS  Google Scholar 

  11. Patel SS, Spencer CM. Latanoprost: a review of its pharmacological properties, clinical efficacy and tolerability in the management of primary open-angle glaucoma and ocular hypertension. Drugs Aging 1996 Nov; 9: 363–78

    Article  PubMed  CAS  Google Scholar 

  12. Serle JB. Pharmacological advances in the treatment of glaucoma. Drugs Aging 1994 Sep; 5: 156–70

    Article  PubMed  CAS  Google Scholar 

  13. Balfour JA, Wilde MI. Dorzolamide: a review of its pharmacology and therapeutic potential in the management of glaucoma and ocular hypertension. Drugs Aging 1997 May; 10: 384–403

    Article  PubMed  CAS  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Brimonidine: a useful new topical treatment for glaucoma and ocular hypertension. Drugs Ther. Perspect 13, 1–4 (1999). https://doi.org/10.2165/00042310-199913010-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-199913010-00001

Keywords

Navigation